Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2019-07-05 Governance Information
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
108年年報及股東會資料 — 2019_1734_20190620F15.pdf
Governance Information Classification · 95% confidence The document is a detailed procedural manual outlining the company's policies and procedures regarding endorsement guarantees and lending of funds to others. It includes specific rules, limits, approval processes, risk assessments, and reporting requirements related to these financial activities. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. Instead, it is a governance document detailing internal rules and procedures for financial risk management and operational controls. Therefore, the document best fits the category of Governance Information (CGR). The document length (6451 characters) supports it being a substantive procedural document rather than a brief announcement.
2019-07-05 Chinese
108年年報及股東會資料 — 2019_1734_20190620F14.pdf
Governance Information Classification · 95% confidence The document is a detailed procedural guideline from a company regarding the acquisition and disposal of important assets, including securities, real estate, equipment, intangible assets, and derivative products. It references compliance with securities laws and regulations, internal control procedures, board approvals, and disclosure requirements. The content is regulatory and procedural in nature, focusing on governance and compliance rather than presenting financial results or earnings. There is no indication that this is an annual report, earnings release, or any form of financial statement. It also does not appear to be a call transcript, audit report, or a direct announcement of voting results or capital changes. The document is a governance-related procedural manual, detailing internal rules and processes for asset transactions and risk management. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2019-07-05 Chinese
108年年報及股東會資料 — 2019_1734_20190620F05.pdf
AGM Information Classification · 100% confidence The document is titled as the minutes of the Annual General Meeting (AGM) of 杏輝藥品工業股份有限公司 for the year 108 (2019). It includes detailed records of the meeting held on June 20, 2019, including attendance, reports presented, resolutions passed, voting results, and discussions on various agenda items such as the 107th fiscal year business report, financial statements, dividend distribution, and amendments to company procedures and articles. The document contains detailed voting results and discussions typical of AGM minutes. It also references attachments like the business report and audit reports but the main document itself is the meeting minutes. Therefore, this document is best classified as AGM Information (AGM-R).
2019-07-05 Chinese
108年年報及股東會資料 — 2019_1734_20190620F17.pdf
Major Shareholding Notification Classification · 95% confidence The document contains a detailed table listing the top ten shareholders and their interrelationships, including shareholding amounts and familial or related party connections. This type of information is typically part of disclosures related to major shareholdings and ownership structures. The document length is 1750 characters, which is relatively short and focused on shareholder information rather than a full financial report or announcement. There is no indication of voting results, management changes, or financial performance data. Therefore, the document best fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or details in significant share ownership levels.
2019-07-05 Chinese
108年年報及股東會資料 — 2018_1734_20190620F04.pdf
Regulatory Filings
2019-07-05 Chinese
108年年報及股東會資料 — 2019_1734_20190620F02.pdf
Regulatory Filings
2019-07-05 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.